Compare Vanguard Mega Cap Growth ETF (MGK) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Novartis AG — how do they compare? Vanguard Mega Cap Growth ETF trades at $87.66, while Novartis AG trades at $154.63 (market cap $290.25B). The key difference: Novartis AG pays a 3.17% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals.
| MGK | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $168.62 |
52-Week Low | $70.70 | $113.50 |
Market Cap | — | $290.25B |
Enterprise Value | — | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights its low expense ratio of 0.05% and concentrated portfolio of 69 large-cap growth stocks, including heavy exposure to technology leaders. A 1:5 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 2026.
MGK offers exposure to top U.S. growth companies but faces risks from high concentration in tech stocks and market volatility. Its long-term performance history and cost efficiency present opportunities for growth-focused investors, though sector-specific downturns could impact returns significantly.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
